Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Center for One Medicine Innovative Translational Research, Gifu University Institute for Advanced Study, Gifu, Japan.
Sci Rep. 2023 Oct 5;13(1):16753. doi: 10.1038/s41598-023-44094-7.
Intradialytic hypotension and arrhythmias are complications of hemodialysis. They are associated with decreased intravascular volume due to reduced ultrafiltration volume, cardiac function, and arterial tone. The vascular endothelial glycocalyx, which exists on the surface of healthy vascular endothelial cells and maintains vascular permeability, has been suggested to be impaired by hemodialysis. This single-center retrospective study evaluated the association between syndecan-1, an endothelial glycocalyx dysfunction marker, and complications of hemodialysis. We enrolled 92 patients who underwent outpatient hemodialysis at Gifu Seiryu Hospital from April to July 2022 (346 hemodialysis sessions). The median duration and time of hemodialysis were 40 months and 4.1 h, respectively. Median serum syndecan-1 levels were 67.7 ng/mL before and 98.3 ng/mL after hemodialysis. Hemodialysis complications were noted in 68 sessions, all of which were hypotension. No correlation between pre-hemodialysis syndecan-1 levels and the incidence of complications was observed. However, a positive correlation between the amount of change in syndecan-1 levels before and after hemodialysis and the incidence of hemodialysis complications was noted. Conversely, syndecan-1 levels did not correlate with brain or atrial natriuretic peptides, suggesting that impairment of the vascular endothelial glycocalyx may be a possible cause of intradialytic hypotension and may be useful in preventing intradialytic hypotension.
透析中低血压和心律失常是血液透析的并发症。它们与由于超滤量减少、心功能和动脉张力降低导致的血管内体积减少有关。血管内皮糖萼存在于健康血管内皮细胞的表面,维持血管通透性,有人认为它会被血液透析破坏。这项单中心回顾性研究评估了内皮糖萼功能障碍标志物 syndecan-1 与血液透析并发症之间的关系。我们招募了 2022 年 4 月至 7 月在岐阜 Seiryu 医院接受门诊血液透析的 92 名患者(346 次血液透析)。透析的中位时间和时间分别为 40 个月和 4.1 小时。中位血清 syndecan-1 水平在血液透析前为 67.7ng/ml,血液透析后为 98.3ng/ml。68 次血液透析中出现并发症,均为低血压。透析前 syndecan-1 水平与并发症发生率之间无相关性。然而,血液透析前后 syndecan-1 水平变化量与血液透析并发症发生率呈正相关。相反,syndecan-1 水平与脑或心房利钠肽无关,提示血管内皮糖萼的损伤可能是透析中低血压的一个可能原因,并可能有助于预防透析中低血压。